Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

Businessweek Archives


Washington Outlook


The Food & Drug Administration is about to make both sides unhappy with its ruling on a long-running dispute over genetically engineered food. The industry has argued that the results of gene-splicing are much the same as conventional cross-breeding, and that the new-style plants usually require no special treatment. Opponents argue that the altered products should be reviewed for safety before reaching market and carry special labels. FDA's split-the-baby solution: It will ask biotech companies to keep the agency abreast of new products, some of which may be subject to review. But the FDA will reject a call for special labeling. Instead, it will require warnings only where the product poses a special hazard, as with a tomato containing a peanut gene that could cause reactions in people allergic to peanuts.EDITED BY STEPHEN H. WILDSTROM

blog comments powered by Disqus